Survey of Lanadelumab for treating hereditary angioedema
Specific Use-Results Survey of TAKHZYRO Subcutaneous Injection 300 Mg Syringe for Hereditary Angioedema with Long-term Administration
Takeda · NCT05397431
This study looks at how well Lanadelumab works for people with hereditary angioedema in Japan by tracking their symptoms and any side effects over a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Sex | All |
| Sponsor | Takeda (industry) |
| Drugs / interventions | Lanadelumab |
| Locations | 1 site (Tokyo) |
| Trial ID | NCT05397431 on ClinicalTrials.gov |
What this trial studies
This observational study surveys the use of Lanadelumab in participants with hereditary angioedema (HAE) in Japan. Participants will receive subcutaneous injections of Lanadelumab according to their clinic's standard practice, while the study will monitor for side effects and improvements in HAE symptoms over a 12-month period. The study sponsor will not influence treatment decisions but will provide guidelines for data collection during the study.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with hereditary angioedema who are receiving Lanadelumab treatment for the first time.
Not a fit: Patients who are not diagnosed with hereditary angioedema or who have previously received Lanadelumab will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the safety and efficacy of Lanadelumab for patients with hereditary angioedema.
How similar studies have performed: While this study is observational, similar studies on Lanadelumab have shown promising results in managing hereditary angioedema.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria - Participants diagnosed with hereditary angioedema (HAE) and treated with Lanadelumab for the first time. Exclusion Criteria - None
Where this trial is running
Tokyo
- Takeda selected site — Tokyo, Japan (RECRUITING)
Study contacts
- Study coordinator: Takeda Contact
- Email: medinfoUS@takeda.com
- Phone: +1-877-825-3327
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hereditary Angioedema, Drug Therapy